Medlive Technology Co., Ltd. (stock code: 02192) has released its monthly return for the period ended 31 January 2026. The total authorised share capital remains at 50,000,000,000 ordinary shares at US$0.00001 par value each, amounting to US$500,000.

As of the end of January, the company’s issued shares (excluding treasury shares) increased from 737,030,875 to 737,960,875, reflecting the exercise of 930,000 share options. These options were exercised under the Pre-IPO Share Option Scheme at an exercise price of RMB0.38, raising RMB353,400 in total. The company did not have any outstanding treasury shares during the period, and all applicable listing requirements regarding public float, set at 24.98%, were met.

Following the exercise, 2,313,625 options remain under the Pre-IPO Share Option Scheme. Meanwhile, the Post-IPO Share Option Scheme remains unchanged, with up to 69,017,600 shares available for potential issuance. No other warrants, convertibles, or other arrangements to issue shares were reported.